<DOC>
	<DOCNO>NCT02250560</DOCNO>
	<brief_summary>The main objective study investigate safety efficacy Replenine®-VF administer continuous infusion appropriate dosage prevent bleed achieve haemostasis patient haemophilia B undergo major surgery .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Replenine®-VF Haemophilia B Patients Undergoing Major Surgery .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Patients moderate severe Haemophilia B ( ≤5 % baseline Factor IX level ) due undergo major surgery , previously treat patient , least 16 year age without inhibitor , currently receive Factor IX concentrate .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>